- Home
- TTGT vs MNMD Comparison
TTGT vs MNMD Comparison
Compare TTGT & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- MNMD
- Stock Information
- Founded
- TTGT 1999
- MNMD 2019
- Country
- TTGT United States
- MNMD United States
- Employees
- TTGT N/A
- MNMD N/A
- Industry
- TTGT Telecommunications Equipment
- MNMD Pharmaceuticals and Biotechnology
- Sector
- TTGT Telecommunications
- MNMD Health Care
- Exchange
- TTGT Nasdaq
- MNMD Nasdaq
- Market Cap
- TTGT 598.8M
- MNMD 509.2M
- IPO Year
- TTGT 2007
- MNMD N/A
- Fundamental
- Price
- TTGT $6.81
- MNMD $8.44
- Analyst Decision
- TTGT Buy
- MNMD Strong Buy
- Analyst Count
- TTGT 6
- MNMD 6
- Target Price
- TTGT $19.33
- MNMD $24.67
- AVG Volume (30 Days)
- TTGT 520.9K
- MNMD 1.3M
- Earning Date
- TTGT 08-11-2025
- MNMD 07-31-2025
- Dividend Yield
- TTGT N/A
- MNMD N/A
- EPS Growth
- TTGT N/A
- MNMD N/A
- EPS
- TTGT N/A
- MNMD N/A
- Revenue
- TTGT $330,125,000.00
- MNMD N/A
- Revenue This Year
- TTGT $74.06
- MNMD N/A
- Revenue Next Year
- TTGT N/A
- MNMD N/A
- P/E Ratio
- TTGT N/A
- MNMD N/A
- Revenue Growth
- TTGT 29.62
- MNMD N/A
- 52 Week Low
- TTGT $6.49
- MNMD $4.70
- 52 Week High
- TTGT $33.08
- MNMD $10.44
- Technical
- Relative Strength Index (RSI)
- TTGT 41.37
- MNMD 48.70
- Support Level
- TTGT $8.33
- MNMD $8.94
- Resistance Level
- TTGT $9.00
- MNMD $10.09
- Average True Range (ATR)
- TTGT 0.62
- MNMD 0.54
- MACD
- TTGT -0.07
- MNMD -0.10
- Stochastic Oscillator
- TTGT 2.23
- MNMD 21.05
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).